Revvity launches eonis q system enabling faster, simplified newborn screening for sma and scid

Waltham, mass.--(business wire)--today, revvity, inc., announced the launch of its eonis™ q system, a ce-ivd declared platform enabling laboratories in countries that accept the ce marking to adopt molecular testing for spinal muscular atrophy (sma) and severe combined immunodeficiency (scid) in newborns. innovative, easy-to-use qpcr workflow for both inherited conditions, immediate detection is critical to advancing a positive outcome. for sma, disease modifying therapies exist to stop progres.
RVTY Ratings Summary
RVTY Quant Ranking